Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials..
Diabetes Res Clin Pract. 177, 108921.
(2021). Effect of exercise on key pharmacokinetic parameters related to metformin absorption in healthy humans: A pilot study..
Scand J Med Sci Sports. 30(5), 858-864.
(2020). Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?.
J Diabetes Sci Technol. 14(4), 745-747.
(2020). Most add-on therapies to metformin have similar effects on HbA1c..
Evid Based Med. 21(6), 223.
(2016).
(2016). Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus..
Hormones (Athens). 14(1), 118-25.
(2015).
(2015). Anticancer effects of metformin on neuroendocrine tumor cells in vitro..
Hormones (Athens). 13(4), 498-508.
(2014). Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy..
Adv Med Sci. 58(1), 38-43.
(2013). Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome..
Hormones (Athens). 12(4), 559-66.
(2013).
(2013).
(2013). Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis..
BMJ. 344, e1369.
(2012). Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome..
Gynecol Endocrinol. 28(1), 20-4.
(2012). The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome..
Endocr J. 58(4), 237-46.
(2011). Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis..
Atherosclerosis. 214(1), 11-9.
(2011).
(2011). Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update..
Curr Opin Obstet Gynecol. 22(6), 466-76.
(2010). The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome..
Drugs. 69(11), 1417-31.
(2009).
(2008).